Alamar Biosciences Surges on Nasdaq Debut, Reaches $1.53 Billion Valuation

Deep News

20 hours ago

Alamar Biosciences saw its stock price jump 33% on its first day of trading on the Nasdaq on Friday, valuing the protein biomarker detection platform company at $1.53 billion. The Fremont, California-based company opened at $22.60 per share, after pricing its initial public offering at $17 per share. Alamar increased the size of its offering, pricing at the top of its $15 to $17 range. It sold approximately 11.3 million shares, raising $191.3 million. Founded in 2018, the company focuses on developing devices that can detect low-concentration protein biomarkers in blood for disease research and diagnostics.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/news/1172815946"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1172815946\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1172815946?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-04-18 01:03","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1172815946","market":"fut","top_or_hot":-1,"title":"Alamar Biosciences Surges on Nasdaq Debut, Reaches $1.53 Billion Valuation","media":"Deep News","content":"<p>Alamar Biosciences saw its stock price jump 33% on its first day of trading on the Nasdaq on Friday, valuing the protein biomarker detection platform company at $1.53 billion.\nThe Fremont, California-based company opened at $22.60 per share, after pricing its initial public offering at $17 per share.\nAlamar increased the size of its offering, pricing at the top of its $15 to $17 range. It sold approximately 11.3 million shares, raising $191.3 million.\nFounded in 2018, the company focuses on developing devices that can detect low-concentration protein biomarkers in blood for disease research and diagnostics.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Alamar Biosciences Surges on Nasdaq Debut, Reaches $1.53 Billion Valuation</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAlamar Biosciences Surges on Nasdaq Debut, Reaches $1.53 Billion Valuation\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1039043262\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/8296859682db4b478146245e72de1922);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Deep News </p>\n<p class=\"h-time\">2026-04-18 01:03</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Alamar Biosciences saw its stock price jump 33% on its first day of trading on the Nasdaq on Friday, valuing the protein biomarker detection platform company at $1.53 billion.\nThe Fremont, California-based company opened at $22.60 per share, after pricing its initial public offering at $17 per share.\nAlamar increased the size of its offering, pricing at the top of its $15 to $17 range. It sold approximately 11.3 million shares, raising $191.3 million.\nFounded in 2018, the company focuses on developing devices that can detect low-concentration protein biomarkers in blood for disease research and diagnostics.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"QDTE","symbol_name":"Roundhill N-100 0DTE Covered Call Strategy ETF","start_time":0,"source_url":"","article_id":"1172815946","we_media_id":"1039043262","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1172815946","pubTimestamp":1776445428,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Deep News","introduction":"Global Stock Market Deep Analysis","home_visible":1,"id":"1039043262","head_image":"https://community-static.tradeup.com/news/8296859682db4b478146245e72de1922"},"summary":"Alamar Biosciences saw its stock price jump 33% on its first day of trading on the Nasdaq on Friday, valuing the protein biomarker detection platform company at $1.53 billion. The Fremont,...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"QDTE":"Roundhill N-100 0DTE Covered Call Strategy ETF","JEPQ":"JPMorgan Nasdaq Equity Premium Income ETF","QQQA":"ProShares Nasdaq-100 Dorsey Wright Momentum ETF","IYW":"美国科技ETF-iShares","TQQQ":"纳指三倍做多ETF","QQQE":"Direxion NASDAQ-100 Equal Weighted Index Shares","QLD":"2倍做多纳斯达克100指数ETF-ProShares","GPIQ":"GOLDMAN SACHS NASDAQ 100 CORE PREMIUM INCOME ETF","TQQY":"GraniteShares YieldBOOST QQQ ETF","QQQY":"Defiance Nasdaq 100 Enhanced Options & 0DTE Income ETF","QYLG":"Nasdaq 100 Covered Call & Growth ETF","ONEQ":"Fidelity NASDAQ Composite Index ETF","SQQQ":"纳指三倍做空ETF","NVIW.SI":"NVDA 3xLongSG261006","QID":"两倍做空纳斯达克指数ETF-ProShares","NBI":"纳斯达克生物技术指数","QQQJ":"Invesco NASDAQ Next Gen 100 ETF","QQQM":"NASDAQ100指数ETF-Invesco","ARTL":"Artelo Biosciences, Inc.","FTEC":"Fidelity MSCI Information Techno","BK4007":"制药","PSQ":"做空纳斯达克100指数ETF-ProShares","QQQ":"纳指100ETF"},"translate_title":"Alamar Biosciences在纳斯达克上市后股价飙升，估值达到15.3亿美元","themeId":"","isJumpTheme":false,"ttsUrl":"https://static.tigerbbs.com/0ac7c2475c2ba592cf49727b2f86a661","symbols_score_info":{"QYLG":1,"IYW":1,"TQQQ":1,"QQQE":1,"QQQM":1,"GPIQ":1,"MNQmain":1,"ONEQ":1,"ARTL":1,"QQQY":1,"QDTE":1,"SQQQ":1,"NBI":1,"QQQ":1,"PSQ":1,"TQQY":1,"FTEC":1,"QQQA":1,"NQmain":1,"QLD":1,"JEPQ":1,"QID":1,"NVIW.SI":1,"QQQJ":1},"content_text":"Alamar Biosciences saw its stock price jump 33% on its first day of trading on the Nasdaq on Friday, valuing the protein biomarker detection platform company at $1.53 billion.\nThe Fremont, California-based company opened at $22.60 per share, after pricing its initial public offering at $17 per share.\nAlamar increased the size of its offering, pricing at the top of its $15 to $17 range. It sold approximately 11.3 million shares, raising $191.3 million.\nFounded in 2018, the company focuses on developing devices that can detect low-concentration protein biomarkers in blood for disease research and diagnostics.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"corporation","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}